Current Hematologic Malignancy Reports

Aims & Scope

his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy.

We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies.

Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists.

An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.

Commentaries from well-known figures in the field are also provided.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	3.3
2024	2.70

Journal Rank

Year	Value
2024	3982

Journal Citation Indicator

Year	Value
2024	385

SJR (SCImago Journal Rank)

Year	Value
2024	1.123

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	48

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies

  Citation: 266

  Authors: Zeina, Beverly P., Andrew M.

• Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

  Citation: 156

  Authors: Bradley M., Zenggang, Alejandro A., Aharon G., Rachel, Meng, Brad, Carlos, Robert A., Rosemary, Pierluigi

• Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

  Citation: 133

  Authors: Lauren, Michael, John, Luke

• Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update

  Citation: 129

  Authors: Neha, Laure, Oliver, Paresh, Irene

• CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease

  Citation: 126

  Authors: Katherine C., Brynn B., Daniel W.

• Incidence and Burden of the Myelodysplastic Syndromes

  Citation: 123

  Authors: Christopher R.

• CAR-T Cell Therapy: the Efficacy and Toxicity Balance

  Citation: 112

  Authors: Karan L., Elizabeth L., Saad S.

• Targeting BTK in CLL: Beyond Ibrutinib

  Citation: 107

  Authors: David A., Jennifer A.

• Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer

  Citation: 98

  Authors: Miguel-Angel, Emily K., Naveen, William A.

• Solitary Plasmacytoma: a Review of Diagnosis and Management

  Citation: 93

  Authors: Andrew, Anuj

---